Table 1
Author, date and countryPatient groupStudy type (level of evidence)OutcomesKey resultsStudy weaknesses
Pfisterer M et al, Switzerland, 1998Patients with acute MIProspectively planned post hoc analyses of the GUSTO-I dataset (a multicentre PRCT)Mortality any atenolol v none30 day mortality was significantly lower in atenolol treated patients.
No atenolol (n=10 073) vs any atenolol (n=30 771)Mortality IV atenolol vs oralMore likely to die (odds ratio 1.3 (95% CI 1, 1.5) p=0.02)
Any intravenous atenolol (n=18 200)vs oral atenolol only (n=12 545) v both intravenous and oral drug (n=16 406)MorbidityMore heart failure, shock, recurrent ischaemia and pacemaker use